menopause Archives

In Depth 20 Sep 2024

Mitigating hot flashes: new therapies for menopause on the rise

New therapies could address menopause symptoms, a field in which many treatment gaps still exist.

September 20, 2024 - 8 minutesmins - By Roohi Mariam Peter

News and Trends 15 May 2023

New menopause drug gets FDA approval

The U.S. Food and Drug Administration has approved Astellas Pharma’s Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Astellas Pharma US, Inc.’s Veozah is the first neurokinin 3 (NK3) receptor antagonist approved by the FDA to treat moderate to severe hot flashes from […]

May 15, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 14 Mar 2023

Astellas menopause study meets endpoints but leukemia drug disappoints

There was good and bad news this week from Japanese company Astellas Pharma Inc. as one of its trials yielded positive results, while another didn’t meet its endpoints. Astellas Pharma announced pivotal phase 3 results for its study of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor […]

March 14, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 30 Sep 2022

Treatment for hot flushes and night sweats accepted for regulatory review by EMA

A treatment for moderate to severe vasomotor symptoms (VMS) has been accepted by the European Medicines Agency (EMA) for regulatory review. Astellas Pharma Inc., submitted a marketing authorization application (MAA) for fezolinetant, an investigational oral, nonhormonal compound. VMS is characterized by hot flushes and/or night sweats which are common menopausal symptoms. Hot flushes The news […]

September 30, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Sep 2022

Astellas ‘encouraged’ by menopause symptom treatment results in China

Astellas Pharma Inc. has announced topline results from its phase 3 MOONLIGHT 3 clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes and/or night […]

September 5, 2022 - 4 minutesmins - By Jim Cornall

More News! 24 Jun 2022

Gurnet Point Capital and Patient Square Capital buy Radius Health for $890M

Global pharmaceutical company, Radius Health Inc, announced this week (June 23) that it has entered into a definitive agreement to be bought out by Gurnet Point Capital and Patient Square Capital in a transaction valued at approximately $890 million. Radius Health is a company focused on addressing unmet medical needs in the areas of bone […]

June 24, 2022 - 3 minutesmins - By Liza Laws

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

menopause

Mitigating hot flashes: new therapies for menopause on the rise

New menopause drug gets FDA approval

Astellas menopause study meets endpoints but leukemia drug disappoints

Treatment for hot flushes and night sweats accepted for regulatory review by EMA

Astellas ‘encouraged’ by menopause symptom treatment results in China

Gurnet Point Capital and Patient Square Capital buy Radius Health for $890M

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!